We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
+$59.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Sector Composition

Rank Sector Weight
1 Healthcare 55.47%
2 Technology 8.46%
3 Industrials 4.82%
4 Financials 2.07%
5 Consumer Discretionary 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GIGGU
201
DELISTED
GigCapital4, Inc. Unit
GIGGU
-175,000
Closed -$1.73M
FOREU
202
DELISTED
Foresight Acquisition Corp. Units
FOREU
-420,000
Closed -$4.16M
ENFAU
203
DELISTED
890 5th Avenue Partners Inc Unit
ENFAU
-98,828
Closed -$983K
TRIL
204
DELISTED
Trillium Therapeutics Inc.
TRIL
-670,459
Closed -$7.2M
SWBK
205
DELISTED
Switchback II Corporation
SWBK
-103,698
Closed -$1.02M
KURIU
206
DELISTED
Alkuri Global Acquisition Corp Unit
KURIU
-150,000
Closed -$1.48M
WPF
207
DELISTED
Foley Trasimene Acquisition Corp.
WPF
-200,000
Closed -$2.01M
FCAC
208
DELISTED
Falcon Capital Acquisition Corp. Class A Common Stock
FCAC
-100,010
Closed -$997K
NRACU
209
DELISTED
Northern Revival Acquisition Corporation Unit
NRACU
-28,000
Closed -$277K
SCAQU
210
DELISTED
Stratim Cloud Acquisition Corp. Unit
SCAQU
-50,000
Closed -$500K

Similar funds

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $59.5M of net new capital in Q2 2021, opening 41 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 378,642 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $49.7M trimmed.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.